“Mounjaro® KwikPen™ 5 mg is the first therapeutic maintenance dose of tirzepatide, commonly prescribed after completion of the 2.5 mg initiation phase. This strength provides clinically meaningful improvements in blood glucose control and begins delivering noticeable benefits in weight reduction and appetite suppression.

At this dosage, tirzepatide enhances insulin secretion in response to meals while simultaneously lowering inappropriate glucagon secretion. The dual GIP and GLP-1 receptor activity improves metabolic efficiency, reduces post-meal glucose spikes, and promotes sustained satiety.

The 5 mg strength is often well tolerated and suitable for many patients as a long-term maintenance dose, depending on individual response. It is administered once weekly, at any time of day, with or without food.

Each KwikPen delivers four pre-measured doses, ensuring dosing accuracy and convenience. The pen mechanism minimizes handling errors and improves patient adherence.”